Bladder Cancer: New Meta-analysis

Oslo, Norway, December 15, 2022: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that a new meta-analysis was published earlier this month in “Photodiagnosis and Photodynamic Therapy”. The Analysis entitled “Comparison of hexaminolevulinate (HAL)-guided versus white light transurethral resection for NMIBC: A systematic review and meta-analysis of randomized controlled trial” evaluated recurrence, recurrence-free survival and progression.

Several Meta-analyses prior to the present one included studies and trials on HAL and 5-ALA. (See Cochrane Analysis from December 2021: https://www.photocure.com/news/new-cochrane-review-on-blue-versus-white-light-for-transurethral-resection-of-non-muscle-invasive-bladder-cancer-confirms-beneficial-effect-of-using-blue-light-on-risk-of-disease-recurrence-and-progression-30). The new meta-analysis features HAL studies only, includes 2,775 patients and looks at both short and long-term outcomes. The analysis shows favorable outcomes on recurrence, recurrence free survival and progression for blue light (HAL-guided) cystoscopy compared to white light cystoscopy.

Find the full publication here: https://doi.org/10.1016/j.pdpdt.2022.103220